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Background:  Transcatheter aortic valve replacement (TAVR) is a newly established therapy for high-risk patients with severe aortic 
stenosis. Given its recent emergence in the United States as an approved treatment, examination of utilization, outcomes and dispersion 
patterns is paramount.
methods:  We analyzed data from the Healthcare Cost and Utilization Project-National Inpatient Sample from August 2011 through 
December 2012. The study sample included patients undergoing TAVR, as identified by ICD-9 CM procedural codes. Baseline 
demographics, hospital characteristics and in-hospital outcomes data including mortality were collected.
results:  1793 patients were identified (national estimate = 8878). Mean age was 81.2 years, 51.8% were male, 83.6% were Caucasian, 
90.1% were Medicare patients and 82.8% of cases were transfemoral. TAVR utilization grew an average of 111% per month while an 
average of 32 additional hospitals per month began performing the procedure (Figure). The most frequent complications included bleeding 
(29.7%), respiratory failure (18.6%) and renal/metabolic issues (16.7%). Median hospital length of stay was 6 days (IQR 4-10) and 4.7% of 
patients died during hospitalization. A majority of cases were performed at large (83.2%), urban teaching (89.3%) hospitals.
conclusion:  Following device approval, TAVR volume and the number of hospitals performing TAVR grew dramatically. Bleeding was the 
most common procedural complication and mortality rate was less than 5%. 
